Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
View ORCID ProfileSrinivas Shenoy, View ORCID ProfileSagar Munjal, View ORCID ProfileSarah Al Youha, View ORCID ProfileMohammad Alghounaim, View ORCID ProfileSulaiman Almazeedi, View ORCID ProfileYousef Alshamali, View ORCID ProfileRichard H Kaszynski, View ORCID ProfileSalman Al-Sabah, Kuwait Clinical Trial Group
doi: https://doi.org/10.1101/2021.11.08.21265884
Srinivas Shenoy
1Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sagar Munjal
2Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sarah Al Youha
3Jaber Al-Ahmad Al-Sabah Hospital, Kuwait, Khalid Ben AbdulAziz Street, South Surra-47781, Kuwait; Email:
Mohammad Alghounaim
4Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Sulaiman Almazeedi
5Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Yousef Alshamali
6Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Richard H Kaszynski
7Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo 150-0013, Japan; Email:
Salman Al-Sabah
8Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted November 09, 2021.
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
Srinivas Shenoy, Sagar Munjal, Sarah Al Youha, Mohammad Alghounaim, Sulaiman Almazeedi, Yousef Alshamali, Richard H Kaszynski, Salman Al-Sabah, Kuwait Clinical Trial Group
medRxiv 2021.11.08.21265884; doi: https://doi.org/10.1101/2021.11.08.21265884
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
Srinivas Shenoy, Sagar Munjal, Sarah Al Youha, Mohammad Alghounaim, Sulaiman Almazeedi, Yousef Alshamali, Richard H Kaszynski, Salman Al-Sabah, Kuwait Clinical Trial Group
medRxiv 2021.11.08.21265884; doi: https://doi.org/10.1101/2021.11.08.21265884
Subject Area
Subject Areas
- Addiction Medicine (403)
- Allergy and Immunology (712)
- Anesthesia (207)
- Cardiovascular Medicine (2969)
- Dermatology (253)
- Emergency Medicine (445)
- Epidemiology (12807)
- Forensic Medicine (12)
- Gastroenterology (830)
- Genetic and Genomic Medicine (4621)
- Geriatric Medicine (423)
- Health Economics (732)
- Health Informatics (2941)
- Health Policy (1073)
- Hematology (393)
- HIV/AIDS (932)
- Medical Education (430)
- Medical Ethics (116)
- Nephrology (475)
- Neurology (4408)
- Nursing (238)
- Nutrition (649)
- Oncology (2295)
- Ophthalmology (652)
- Orthopedics (260)
- Otolaryngology (327)
- Pain Medicine (281)
- Palliative Medicine (84)
- Pathology (502)
- Pediatrics (1200)
- Primary Care Research (502)
- Public and Global Health (7005)
- Radiology and Imaging (1544)
- Respiratory Medicine (921)
- Rheumatology (444)
- Sports Medicine (386)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)